Artificial intelligence to accelerate malaria research

IMAGE: InSilico study reveals how E64 approaches, binds to, and inhibits falcipain-2 of Plasmodium falciparum that causes malaria in humans. Monday, November 12, 2018, Taipei, Taiwan, Republic of China - Insilico Taiwan, a Taipei-based subsidiary of Insilico Medicine, developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, announces the publication of a new research paper titled "In Silico Study Reveals How E64 Approaches, Binds to, and Inhibits Falcipain-2 of Plasmodium falciparum that Causes Malaria in Humans" in Scientific Reports - a scientific journal published by the Nature Publishing Group. Malaria is one of the world's oldest infectious diseases that still causes a lot of health problems in many tropical countries. Plasmodium falciparum, the most dangerous human malaria parasite, is believed to cause hundreds of millions of illnesses and about half a million deaths a year. Inhibitors of FP2 block haemoglobin destruction and parasite development, suggesting that FP2 inhibition is a promising target for antimalarial therapy.